Mesoblast shares are trading higher after the FDA earlier in the week informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application f...

Mesoblast Limited Sponsored ADR +3.45%

Mesoblast Limited Sponsored ADR

MESO

7.49

+3.45%

Mesoblast shares are trading higher after the FDA earlier in the week informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via